Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment.

Atherosclerosis is a well-known risk factor of cardiovascular disease development. This research presents the AC mode of chemotherapy-related homocysteine level changes, with the simultaneous trimetazidine administration as a possible therapeutic inhibitor of chemotherapy-associated disturbances of morphofunctional homeostasis, for assessing the possible normalization effects. In order to the implementation of this experimental research, 80 Wistar rats were used. The chemotherapy was administered in AC mode. Trimetazidine was used as a stabilizer of homocysteine concentration. Analysis of homocysteine concentration was carried out by quantitative enzyme immunoassay. Given results state that AC-mode of chemotherapy modulates homocysteine production, a known risk factor for endothelial dysfunction development. At the same time, trimetazidine showed an unexpected limitation of homocysteine concentration. The obtained data indicate that hyperhomocysteinemia also plays a particular role in implementing the chemotherapy-induced cardiovascular disturbances continuum. While homocysteine's stabilizing properties of trimetazidine appear to be quite promising, withal further research is needed.